dc.creatorBaroni Pietto, Maria Constanza
dc.creatorLev, Paola Roxana
dc.creatorGlembotsky, Ana Claudia
dc.creatorMarín Oyarzún, Cecilia P.
dc.creatorGomez, Graciela
dc.creatorCollado, Victoria
dc.creatorPisoni, Cecilia
dc.creatorGomez, Ramiro A.
dc.creatorGrodzielski, Matías
dc.creatorGonzalez, Jacqueline
dc.creatorMariño, Karina Valeria
dc.creatorHeller, Paula Graciela
dc.creatorGoette, Nora Paula
dc.creatorMarta, Rosana Fernanda
dc.date.accessioned2021-12-05T21:24:59Z
dc.date.accessioned2022-10-15T13:36:52Z
dc.date.available2021-12-05T21:24:59Z
dc.date.available2022-10-15T13:36:52Z
dc.date.created2021-12-05T21:24:59Z
dc.date.issued2021-11
dc.identifierBaroni Pietto, Maria Constanza; Lev, Paola Roxana; Glembotsky, Ana Claudia; Marín Oyarzún, Cecilia P.; Gomez, Graciela; et al.; Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus; Taylor & Francis Ltd; Platelets; 11-2021; 1-12
dc.identifier0953-7104
dc.identifierhttp://hdl.handle.net/11336/148213
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4392069
dc.description.abstractSystemic lupus erythematosus (SLE) is an autoimmune condition developing thrombocytopenia in about 10?15% of cases, however, mechanisms leading to low platelet count were not deeply investigated in this illness. Here we studied possible causes of thrombocytopenia, including different mechanisms of platelet clearance and impairment in platelet production. Twenty-five SLE patients with and without thrombocytopenia were included. Platelet apoptosis, assessed by measurement of loss of mitochondrial membrane potential, active caspase 3 and phosphatidylserine exposure, was found to increase in thrombocytopenic patients. Plasma from 67% SLE patients (thrombocytopenic and non-thrombocytopenic) induced loss of sialic acid (Ricinus communis agglutinin I and/or Peanut agglutinin binding) from normal platelet glycoproteins. Concerning platelet production, SLE plasma increased megakaryopoiesis (evaluated using normal human cord blood CD34+ hematopoietic progenitors), but inhibited thrombopoiesis (proplatelet count). Anti-platelet autoantibody depletion from SLE plasma reverted this inhibition. Overall, abnormalities were more frequently observed in thrombocytopenic than non-thrombocytopenic SLE patients and in those with active disease (SLEDAI≥5). In conclusion, platelet clearance due to apoptosis and desialylation, and impaired platelet production mainly due to inhibition of thrombopoiesis, could be relevant mechanisms leading to thrombocytopenia in SLE. These findings could provide a rational basis for the choice of proper therapies to correct platelet counts in these patients.
dc.languageeng
dc.publisherTaylor & Francis Ltd
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1080/09537104.2021.1988547
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1080/09537104.2021.1988547?journalCode=iplt20
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAUTOANTIBODIES
dc.subjectMEGAKARYOCYTES
dc.subjectPLATELETS
dc.subjectSYSTEMIC LUPUS ERYTHEMATOSUS
dc.subjectTHROMBOCYTOPENIA
dc.titlePathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución